Loading stock data…
GL
$159.33+2.20 (+1.40%)
Market ClosedLast close Jun 9
Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Globe Life Inc. in the Financial Services sector is trading at $159.33. Wall Street consensus targets $175.91 (11 analysts), implying a +10.4% move over the next 12 months. The stock is currently near its 52-week high of $160.74, remaining 12.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +10.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JPMBACGS
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$159.33
Potential Downside
0%
Whystock Fair Value$159.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$175.91+10.4%
Range$147.00 – $208.00
Fundamentals
Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States. It operates in three segments: Life Insurance, Supplemental Health Insurance...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.72%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.35%
Volume
Today's trading volume
596,492
Recent News
Zacks.com featured highlights include Ross Stores, TE Connectivity, Cenovus Energy, Globe Life and The Charles Schwab
Ross Stores, TE Connectivity, Cenovus Energy, Globe Life and Charles Schwab stand out for high ROE as investors navigate volatile markets.
These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
MetLife, Globe Life, and Unum Group are hitting 52-week highs as P&C premiums decline, rewarding insurers with life, group benefits, and health exposure.
Buy 5 Stocks With High ROE as Markets Swing on War Skirmishes
ROST joins TEL, CVE, GL and SCHW high-ROE cash cows screened for $1B+ cash flow as markets whip on Iran-U.S. skirmishes.
Raised 2026 Guidance and Analyst Downgrade Might Change The Case For Investing In Globe Life (GL)
Earlier in 2026, Globe Life Inc. reported first-quarter net operating income rising 11.7% year over year, with higher life and health premiums and investment income, but earnings slightly missed estimates due to elevated expenses, while management raised full-year 2026 net operating income guidance to US$15.40–US$15.90 per diluted share. A major analyst subsequently downgraded the stock’s rating even as they acknowledged the improved earnings outlook, underscoring a cautious stance toward...
Morgan Stanley And Two Insurance Stocks Hit New Highs
Morgan Stanley stock is in a buy zone of a base. A biometric identity name hit a new high after rebounding following a sell signal.